Tags

Type your tag names separated by a space and hit enter

Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Tunis Med. 2009 Jun; 87(6):380-1.TM

Abstract

AIM

Bisphosphonates are powerful agents able to prevent bone loss. The objective of the study was to evaluate the efficacy and tolerability of risedronate once a week (35 mg) compared with risedronate 5 mg once daily in women with osteoporosis.

METHODS

A randomized, double-blind, active-controlled study enrolled 102 postmenopausal women aged 66.5 + 7.5 years with osteoporotic fractures. All women received risedronate during 6 months. Group 1 (G1, n=51) received risedronate 5 mg once daily and group 2 (G2, n=51) received 35 mg once a week. Serum alkaline phosphatase (ALP), bone alkaline phosphatase (bone ALP), serum C-terminal telopeptide of type I collagen (CTX) were measured at baseline, 3 months and 6 months after treatment in the two groups.

RESULTS

We noted no significant difference in markers between women of the 2 groups. After 3 months, bone ALP and CTX decreased (respectively -22.1% and -47.6%) in the 2 groups with no significant difference between them. After 6 months study, bone ALP and CTX decreased respectively by -46.5% and -62.9% with no statistically significant difference between study groups for bone markers.

CONCLUSION

Our study found that treatment with once weekly risedronate 35 mg is able to decrease CTX and bone ALP compared with risedronate 5 mg once daily, in postmenopausal women with osteoporotic fractures. We didn't find adverse events with the 35 mg once-a-week dose group compared to the once-daily dose group. Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose. This therapeutic protocol may provide an alternative for patients who prefer once-a-week oral dosing.

Authors+Show Affiliations

Department of Clinical Biochemistry, Charles Nicolle Hospital, Tunis.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19927782

Citation

Bahlous, Afef, et al. "Effects of Risedronate On Bone Turnover Markers in Osteoporotic Postmenopausal Women: Comparison of Two Protocols of Treatment." La Tunisie Medicale, vol. 87, no. 6, 2009, pp. 380-1.
Bahlous A, Bouzid K, Sahli H, et al. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. Tunis Med. 2009;87(6):380-1.
Bahlous, A., Bouzid, K., Sahli, H., Sallami, S., & Abdelmoula, J. (2009). Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. La Tunisie Medicale, 87(6), 380-1.
Bahlous A, et al. Effects of Risedronate On Bone Turnover Markers in Osteoporotic Postmenopausal Women: Comparison of Two Protocols of Treatment. Tunis Med. 2009;87(6):380-1. PubMed PMID: 19927782.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. AU - Bahlous,Afef, AU - Bouzid,Kahena, AU - Sahli,Héla, AU - Sallami,Slaheddine, AU - Abdelmoula,Jaouda, PY - 2009/11/26/entrez PY - 2009/11/26/pubmed PY - 2010/1/7/medline SP - 380 EP - 1 JF - La Tunisie medicale JO - Tunis Med VL - 87 IS - 6 N2 - AIM: Bisphosphonates are powerful agents able to prevent bone loss. The objective of the study was to evaluate the efficacy and tolerability of risedronate once a week (35 mg) compared with risedronate 5 mg once daily in women with osteoporosis. METHODS: A randomized, double-blind, active-controlled study enrolled 102 postmenopausal women aged 66.5 + 7.5 years with osteoporotic fractures. All women received risedronate during 6 months. Group 1 (G1, n=51) received risedronate 5 mg once daily and group 2 (G2, n=51) received 35 mg once a week. Serum alkaline phosphatase (ALP), bone alkaline phosphatase (bone ALP), serum C-terminal telopeptide of type I collagen (CTX) were measured at baseline, 3 months and 6 months after treatment in the two groups. RESULTS: We noted no significant difference in markers between women of the 2 groups. After 3 months, bone ALP and CTX decreased (respectively -22.1% and -47.6%) in the 2 groups with no significant difference between them. After 6 months study, bone ALP and CTX decreased respectively by -46.5% and -62.9% with no statistically significant difference between study groups for bone markers. CONCLUSION: Our study found that treatment with once weekly risedronate 35 mg is able to decrease CTX and bone ALP compared with risedronate 5 mg once daily, in postmenopausal women with osteoporotic fractures. We didn't find adverse events with the 35 mg once-a-week dose group compared to the once-daily dose group. Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose. This therapeutic protocol may provide an alternative for patients who prefer once-a-week oral dosing. SN - 0041-4131 UR - https://www.unboundmedicine.com/medline/citation/19927782/Effects_of_risedronate_on_bone_turnover_markers_in_osteoporotic_postmenopausal_women:_comparison_of_two_protocols_of_treatment_ L2 - http://www.latunisiemedicale.com/article-medicale-tunisie.php?article=1101 DB - PRIME DP - Unbound Medicine ER -